DXCM · PEAD ↑ 94

Dexcom reported Q3 2026 EPS of $0.73 on 2026-10-29, beating the $0.66 consensus by $0.07 (+10.6%).

Print-day reaction was +1.7% versus the prior close, a measured but positive initial read on the beat. The overnight gap to T+1 open added another +2.0%, signalling sustained buying interest with no after-hours fade. Over the following two trading sessions the stock drifted a further +0.8%, holding the move without meaningful give-back. Cumulative abnormal return of +7.9% versus SPY.US — which returned −2.3% over the same window — places this firmly in PEAD long territory; the documented drift pattern is tracked through the holding window ending 2027-01-26.